Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$33.30 USD
-0.32 (-0.95%)
Updated May 31, 2024 04:00 PM ET
After-Market: $33.31 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Celldex Therapeutics, Inc. [CLDX]
Reports for Purchase
Showing records 221 - 240 ( 411 total )
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Perception May Drive Today but Real Impact is Only Modest; Target to $39
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Post-ASCO, Now Marching Toward the Final "ACT IV"; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updated Rintega ReACT Data: Continues to Demonstrate Statistically Significant Overall Survival in Recurrent Avastin- Naive Glioblastoma Patients
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updated Rintega ReACT Data: Continues to Demonstrate Statistically Significant Overall Survival in Recurrent Avastin- Naive Glioblastoma Patients
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moons Aligning Nicely for Rintega as Data Continue to Impress; Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 25th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 25th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Results; Next Stop, ASCO with ReACT and METRIC Data
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Earnings, Pipeline Advancing, We Continue to See Early Rintega Approval, Reiterate OP Rating and $32 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - The State of Immunotherapy 3.0: "Silver Linings Immunobook"; Bright Horizons
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Varli Expansion Continues; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Varlilumab''s ''Durable'' Appeal with New Collaboration Combo Study
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2014 Results; Prepping For Rintega Potential Success; Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J